Deal Snapshot
Sensei Biotherapeutics Closes Acquisition of Alvaxa Biosciences
Thursday 28 May 2020

US-based clinical-stage biopharmaceutical company Sensei Biotherapeutics, Inc., developing precision immuno-oncology therapies, has closed the acquisition of Alvaxa Biosciences, Inc., a camelid antibody therapeutics company with technology licensed from Fred Hutchinson Cancer Research Center, the company said.

Under the terms of the agreement, Sensei will acquire Alvaxa Biosciences and its existing camelid nanobody libraries, expertise in nanobody discovery, as well as its partnership with Hope Farms, LLC, a United States Department of Agriculture licensed Alpaca farm, for the generation of future alpaca-derived nanobodies.

Date Published: 28/05/2020